Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2014
03/18/2014US8674044 Immobilization of membrane proteins onto supports via an amphiphile
03/18/2014US8674033 Biodegradable phase separated segmented multi block co-polymers
03/18/2014US8673987 Surfactant composition
03/18/2014US8673986 Coacervate having an ionic polymer mixed with the adhesive protein of a mussel or of a species of the variome thereof
03/18/2014US8673973 Method for treating ocular hypertension and glaucoma
03/18/2014US8673359 Nanoparticle compositions and methods for improved oral delivery of active agents
03/18/2014US8673343 Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels and for the prevention and treatment of cancer
03/18/2014US8673334 Stent coatings comprising hydrophilic additives
03/18/2014US8673328 Topical skin composition comprising shea butter, jojoba oil, petroleum jelly, stearic acid, magnesium sulfate, zinc oxide, glycerin, and water
03/18/2014US8673297 Chlorine dioxide based cleaner/sanitizer
03/18/2014US8673296 Method and composition for producing a cellular allogeneic vaccine
03/18/2014US8673281 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
03/18/2014US8673280 Pharmaceutical composition for intracellar acidification with cis-urocanic acid
03/18/2014US8673266 Polyvinyl alcohol microspheres, injectable solutions and therapeutic uses of the same
03/18/2014US8673264 Injectable biomaterial
03/18/2014US8673190 Method for manufacturing dosage forms
03/18/2014CA2752522C Delivery of active agents using a chocolate vehicle
03/18/2014CA2691695C Glp-1-fc fusion protein formulation
03/18/2014CA2680945C Anti-pdgfralpha antibodies
03/18/2014CA2655788C Skin external preparation containing triterpenic acid
03/18/2014CA2637065C Use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances
03/18/2014CA2614764C Sustained release of antiinfectives
03/18/2014CA2569788C Tumor specific antibody
03/18/2014CA2553313C Cationic graft-copolymer for non-viral gene delivery vector
03/18/2014CA2530364C Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
03/18/2014CA2469588C Highly concentrated stable meloxicam solutions for needleless injection
03/17/2014CA2826786A1 Multi-encapsulated formulations made with oxidized cellulose
03/13/2014WO2014039781A1 Treating hearing loss
03/13/2014WO2014039682A1 Antibody formulations and uses thereof
03/13/2014WO2014039533A2 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
03/13/2014WO2014039503A1 Bolaamphiphilic compounds, compositions and uses thereof
03/13/2014WO2014039245A1 Method of creating hydrogels through oxime bond formation
03/13/2014WO2014039185A1 Polymeric nanoparticles in a thermosensitive gel for coital-independent vaginal prophylaxis of hiv
03/13/2014WO2014039012A1 Hyaluronic acid-based drug delivery systems
03/13/2014WO2014038963A1 Dendrimer scaffolds for pharmaceutical use
03/13/2014WO2014038829A1 Method for selectively activating magnetic nanoparticle and selectively activated magnetic nanoparticle
03/13/2014WO2014038641A1 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
03/13/2014WO2014038593A2 Granulated material for tablet that rapidly disintegrates in mouth
03/13/2014WO2014038558A1 Molecular assembly using branched amphiphilic block polymer, and drug transportation system
03/13/2014WO2014038168A1 Functional substance, method for permeating bioactivating agent and functional substance into living body, functional substance-dispersing device, and air cleaner
03/13/2014WO2014037883A1 Topical antimicrobial formulations
03/13/2014WO2014037881A1 Compositions and methods for parkinson's disease treatment by bdnf-flag gene transfer through neurotensin polyplex to nigral dopamine neurons
03/13/2014WO2014037680A1 High concentration aqueous protein solution having reduced viscosity
03/13/2014WO2014037596A1 Release of substances into senescent cells
03/13/2014WO2014037589A2 New antimicrobial compositions
03/13/2014WO2014037585A1 Bioconjugates comprising modified antigens and uses thereof
03/13/2014WO2014037260A1 Compounds for the treatment of neurodegenerative disorders
03/13/2014WO2014036649A1 Rapid formation of chitosan sponges using guanosine 5' -diphosphate: injectable scaffolds for tissue regeneration and drug delivery
03/13/2014WO2014015024A3 Inhibitors of alpha-crystallin aggregation for the treatment for cataract
03/13/2014WO2014004549A3 Anti-mesothelin binding proteins
03/13/2014WO2013040242A3 Dermal filler compositions for fine line treatment
03/13/2014WO2013030702A8 Anthelmintic formulations and treatments
03/13/2014US20140073802 Maleimidyl polymer derivatives
03/13/2014US20140073761 Conjugates containing hydrophilic spacer linkers
03/13/2014US20140073680 Bladder cancer treatment and methods
03/13/2014US20140073671 Orally disintegrating tablet
03/13/2014US20140073617 Panaxadiol-containing composition
03/13/2014US20140073615 Treatment of Psoriasis
03/13/2014US20140073604 Ladder-Frame Polyether Conjugates
03/13/2014US20140073602 Nitric oxide delivering hydroxyalkyl starch derivatives
03/13/2014US20140073589 Amphetamine Prodrugs
03/13/2014US20140073588 Glue composition for lung volume reduction
03/13/2014US20140073584 Thienopyranones as Kinase Inhibitors
03/13/2014US20140073577 Potent and selective inhibitors of nav1.3 and nav1.7
03/13/2014US20140073570 Pharmaceutical composition and methods for peptide treatment
03/13/2014US20140072646 Thyroid hormone analogs and methods of use
03/13/2014US20140072645 Dosage forms for oral administration and methods of treatment using the same
03/13/2014US20140072644 Anti-misuse microparticulate oral pharmaceutical form
03/13/2014US20140072643 Methods of treating cancer
03/13/2014US20140072633 Polymer-epothilone conjugates, particles, compositions and related methods of use
03/13/2014US20140072631 Combinations and modes of administration of therapeutic agents and combination therapy
03/13/2014US20140072630 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
03/13/2014US20140072627 Formulations for enhanced bioavailability of orally administered polar agents
03/13/2014US20140072625 Gastric Reflux Resistant Dosage Forms
03/13/2014US20140072623 Gastric retained gabapentin dosage form
03/13/2014US20140072618 Topical delivery of l-arginine to cause beneficial effects
03/13/2014US20140072616 Lyophilization of Virosomes
03/13/2014US20140072615 Transdermal hormone delivery system: compositions and methods
03/13/2014US20140072614 Rapidly acting dry sealant and methods for use and manufacture
03/13/2014US20140072612 Rolled collagen carrier
03/13/2014US20140072610 Bioabsorbable tracheal stent, and method of manufacturing thereof
03/13/2014US20140072604 Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
03/13/2014US20140072600 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
03/13/2014US20140072588 Absorption of therapeutic agents across mucosal membranes or the skin
03/13/2014US20140072587 Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
03/13/2014US20140072586 Antibody drug conjugates (adc) that bind to 158p1d7 proteins
03/13/2014US20140072559 Highly concentrated aqueous protein solution with reduced viscosity
03/13/2014US20140072528 Immunotherapy
03/13/2014US20140072526 Method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant
03/13/2014US20140072518 Polytetrafluoroethylene co-polymer emulsions
03/13/2014US20140072514 Polytetrafluoroethylene co-polymer emulsions
03/13/2014US20140072513 Sugar and peg functionalized polyacetals with controlled ph-dependent degradation
03/13/2014US20140072511 Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
03/13/2014US20140070446 Sustained-release solid preparation for oral use
03/13/2014DE102012108560A1 Nichtkovalente selbstorganisierende Hydrogelmatrix für biotechnologische Anwendungen Non-covalent self-assembling hydrogel matrix for biotechnological applications
03/12/2014EP2705856A1 Compounds for the treatment of neurodegenerative disorders
03/12/2014EP2705835A1 Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
03/12/2014EP2705763A1 Method for utilizing extraction residue of yeast extract
03/12/2014EP2705062A1 Novel shear-stable polymer systems, the production thereof, and the use thereof as thickeners
03/12/2014EP2704750A2 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
1 ... 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 ... 1712